RNA for treatment of autoimmune diseases
The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
1. A method of treating an autoimmune disease in a subject,
comprising administering to the subject a composition comprising a non-immunogenic RNA encoding a peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment, wherein the non-immunogenic RNA comprises 1-methyl-pseudouridine, wherein the non-immunogenic RNA is formulated in a F12 liposome, and wherein the composition does not comprise dsRNA.
2. A method of inducing tolerance to autoreactive T cells in a subject, comprising administering to the subject a composition comprising a non-immunogenic RNA encoding a peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment, wherein the non-immunogenic RNA comprises 1-methyl-pseudouridine, wherein the non-immunogenic RNA is formulated in a F12 liposome, and wherein the composition does not comprise dsRNA.
3. The method of claim 2 , wherein the subject has an autoimmune disease.
4. The method of claim 2 , wherein the non-immunogenic RNA when administered does not result in activation of dendritic cells, activation of T cells and/or secretion of IFN-alpha.
5. The method of claim 2 , wherein the non-immunogenic RNA is mRNA or in vitro transcribed RNA.
6. The method of claim 2 , wherein the autoantigen is a T cell-antigen, CNS-derived, a myelin antigen, or Myelin Oligodendrocyte Glycoprotein (MOG).
7. The method of claim 2 , wherein the peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment comprises amino acids 35 to 55 of Myelin Oligodendrocyte Glycoprotein (MOG).
8. The method of claim 2 , wherein the non-immunogenic RNA is formulated in a delivery vehicle.